Resolution criteria

This market will resolve to "Yes" if, by December 31, 2030, a peer-reviewed clinical trial demonstrates that GLP-1 receptor agonists significantly reduce osteoarthritis symptoms in humans. The trial must be published in a reputable medical journal and show statistically significant improvements in osteoarthritis symptoms compared to a control group. The primary outcome measures should include validated assessments of pain, physical function, and/or structural changes in the affected joints. If no such study is published by the specified date, the market will resolve to "No". If such a study sets out to investigate this and finds no significant reduction of such symptoms before market end date the market also resolves "No".